Drugs / BSB-2002
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07583303 | Dec 2026 → Apr 2027 expected | acute myeloid leukemia | City of Hope Medical Center | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07566585 | Apr 2026 → Aug 2027 expected | acute myeloid leukemia with mutated NPM1 | BlueSphere Bio, Inc | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BSB-2002 | “followed by BSB-2002 IV over 30 minutes on day 0” NCT07583303 ↗ |
| Modality | Cell therapy | “a new type of cellular therapy” NCT07566585 ↗ |
| Route | Intravenous | “as a single IV infusion at day 1” NCT07566585 ↗ |
| Target | NPM1 | “mutant NPM1-directed T cell receptor (TCR)” NCT07566585 ↗ |